Mazdutide is a strange one to look up, because most pages get its status wrong in one of two directions. Some treat it like an unapproved research chemical. Others imply you can just get it. Neither is right. Here's the actual picture.
What mazdutide actually is
Mazdutide (lab codes IBI362 and LY3305677) is a peptide — a short chain of amino acids, which are the tiny building blocks that make up protein. It's man-made and designed to copy signals your body already uses.
Scientists call it a dual agonist. An *agonist* switches a receptor on — think of a key fitting a lock. Mazdutide fits two locks:
- GLP-1 — the 'I'm full' signal. Same target as semaglutide (the drug in Ozempic and Wegovy). Switching it on curbs appetite and slows how fast food leaves your stomach.
- Glucagon — a signal that affects how your body burns energy and handles stored fat.
Interestingly, mazdutide is based on oxyntomodulin, a hormone your own gut naturally releases after a meal that happens to hit both of those signals already. So rather than inventing a molecule from scratch, the developers took something the body already does and made a longer-lasting version of it.
It's developed by Innovent Biologics, a Chinese biotech, under license from Eli Lilly, the American drug giant behind Mounjaro and Zepbound.
What it's studied for
- Obesity and weight loss — the main use, and what it was first approved for in China
- Type 2 diabetes — a condition where blood sugar stays too high
- Fatty liver disease, obstructive sleep apnea, and alcohol use disorder — all still being tested, not settled
The legal status — the part everyone gets wrong
This is the honest answer, and it has two halves:
In China, mazdutide is an approved medicine. China's regulator approved it in June 2025 for long-term weight management in adults, and again in September 2025 for blood sugar control in type 2 diabetes. It's sold there under the brand name Xinermei. That's a real approval, based on real trial data reviewed by a real regulator.
Outside China, it isn't. The FDA has not approved it. The EMA has not approved it. Most other regulators haven't either. If you're in the US, the UK, Canada, or the EU, mazdutide is not a medicine you can be prescribed, and no doctor there is monitoring anyone on it.
What the evidence really shows
The evidence here is genuinely strong — stronger than for most things covered on this site. Mazdutide has finished, published Phase 3 trials in people, which is the big final stage of testing, and they appeared in two of the most demanding medical journals in the world.
| Trial | What it tested | What it found |
|---|---|---|
| GLORY-1 (Phase 3, published 2025) | 610 Chinese adults with obesity or overweight, over 48 weeks, against a placebo (a dummy injection) | Clear, substantial weight loss compared with placebo, with the higher dose doing more |
| GLORY-2 (Phase 3, published 2026) | 461 Chinese adults with moderate to severe obesity, over 60 weeks, against placebo | Larger weight loss again; the great majority of people on mazdutide lost at least 5% of their body weight |
| Ongoing | Fatty liver disease, sleep apnea, adolescents, head-to-head against semaglutide | Not finished |
There is one real limitation worth naming, and it isn't a knock on the science: almost all of this research was done in China, in Chinese participants. That's a perfectly valid population to study — but regulators like the FDA generally want data that reflects the population they're approving for. It's part of why an approval in one country doesn't automatically travel to another.
And the side effects are not a footnote. In GLORY-2, roughly half of people on mazdutide reported vomiting and nausea, and around 40% reported diarrhea. Most cases were mild to moderate, and few people quit over it — but 'common gut misery, usually manageable' is an honest description of what these drugs do to a lot of people.
What the research points to
- Finished Phase 3 trials in people, published in NEJM and JAMA
- Substantial weight loss versus placebo, consistent across two large trials
- A real regulatory approval in China, based on that data
- A sound rationale: it's modeled on oxyntomodulin, a hormone your gut already makes
What it does NOT prove
- That it's approved or available where you live, unless you're in China
- That the data transfers cleanly to other populations — nearly all participants were Chinese
- That it beats approved drugs like semaglutide — the head-to-head trials aren't finished
- That a vial bought online is the approved product, or is safe, or is even mazdutide
Who talks about it — and why to be careful
Mazdutide gets pushed hard by grey-market sellers, and the China approval is used as a selling point: 'it's an approved drug!' Read that carefully. It's approved *there*, for a specific product, made under inspection, given to patients whose doctors are watching them. None of that describes an unlabeled vial shipped internationally. If anything, the fact that a legitimate approved version exists makes the counterfeit market around it more attractive, not less.
What this does not mean
- This does not mean mazdutide is approved or available where you live — outside China, it isn't.
- This does not mean the China approval makes online 'research' versions legitimate; those are unregulated copies, not the approved product.
- This does not mean the trial results automatically apply to everyone — nearly all participants studied so far were in China.
- This is general education, not medical advice or a recommendation to use mazdutide.